# Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment

> **NCT05167500** · — · COMPLETED · sponsor: **Fundación GECP** · enrollment: 118 (actual)

## Conditions studied

- Metastatic Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT05167500
- **Lead sponsor:** Fundación GECP
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-09
- **Primary completion:** 2022-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2023-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05167500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05167500, "Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment". Retrieved via AI Analytics 2026-09-20 from https://api.ai-analytics.org/clinical/NCT05167500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*